Skip to main content
Aurora Cannabis Inc. logo

Aurora Cannabis Inc. — Investor Relations & Filings

Ticker · ACB ISIN · CA05156X8504 TSX Manufacturing
Open in API
Filings indexed 364 across all filing types
Latest filing 2024-02-08 Regulatory Filings
Country CA Canada
Listing TSX ACB

About Aurora Cannabis Inc.

https://www.auroramj.com/

Aurora Cannabis Inc. is a global leader in the production and distribution of cannabis and cannabis-derivative products. The company cultivates and sells a portfolio of products for both medicinal and recreational markets. Recognized as Canada's largest medical cannabis company and a trusted provider, Aurora focuses on innovative, science-based medical cannabis offerings, including dried flower and various derivative formats such as oils and edibles. The company maintains operations across 12 countries, emphasizing high-quality cultivation and rigorous product development to serve patients and consumers worldwide.

Recent filings

Filing Released Lang Actions
52-109F2 - Certification of interim filings - CEO (E).pdf
Regulatory Filings Classification · 95% confidence The document is a Form 52-109F2 Certification of Interim Filings by the CEO of Aurora Cannabis Inc. It certifies the review and fair presentation of the interim financial report and interim MD&A for the period ended December 31, 2023. The content is primarily an officer certification regarding the interim filings, internal controls, and disclosure controls. It does not contain the actual interim financial statements or substantive financial data but rather attests to their accuracy and compliance. According to the Certification Rule, such officer certifications should be classified as Regulatory Filings (RNS) rather than as the interim report itself (IR). The document length is 3782 characters, which is relatively short and consistent with a certification letter rather than a full interim report.
2024-02-08 English
Interim financial statements/report – English.pdf
Interim / Quarterly Report Classification · 100% confidence The document is titled 'Condensed Consolidated Interim Financial Statements (Unaudited)' for the three and nine months ended December 31, 2023 and 2022. It contains detailed financial statements including Statements of Financial Position, Statements of Loss and Comprehensive Loss, Statements of Changes in Equity, and accompanying notes. The presence of interim period financial data (quarterly and nine months) and the unaudited nature indicates this is a quarterly or interim financial report rather than a full annual report. The document length is substantial (15,000 characters) and contains actual financial data and analysis, not just an announcement or certification. Therefore, the document fits the definition of an Interim / Quarterly Report (IR). 9M 2024
2024-02-08 English
Interim MD&A - English.pdf
Interim / Quarterly Report Classification · 100% confidence The document is titled 'Management’s Discussion & Analysis' (MD&A) for the three and nine months ended December 31, 2023. It contains detailed financial and operational analysis, including business overview, financial review, liquidity, capital resources, accounting policies, and risk factors. The document references interim financial statements prepared under IAS 34 (Interim Financial Reporting) and discusses quarterly results, indicating it is a comprehensive interim report rather than a brief announcement or a full annual report. The length (15,000 characters) and content confirm it is a substantive financial report. Therefore, the document fits the definition of an Interim / Quarterly Report (IR). Q3 2024
2024-02-08 English
News release - English.pdf
Interim / Quarterly Report Classification · 95% confidence The document is a detailed announcement of Aurora Cannabis's financial and operational results for the third quarter of fiscal year 2024, including comprehensive financial data such as net revenue, adjusted gross profit, adjusted EBITDA, segment revenues, and operational highlights. It also discusses business developments like the acquisition of MedReleaf Australia and provides forward-looking statements and expectations for the next quarter. The presence of detailed financial figures, segment analysis, and management commentary indicates this is a quarterly financial report rather than a brief earnings release or a simple announcement. The document length (15,000 characters) and depth of financial data confirm it is a substantive interim/quarterly report. Therefore, the appropriate classification is Interim / Quarterly Report (IR). Q3 2024
2024-02-08 English
News release - English.pdf
Merger & Acquisition Classification · 95% confidence The document is a press release dated February 8, 2024, announcing Aurora Cannabis's acquisition of MedReleaf Australia. It details the transaction terms, strategic rationale, management commentary, and forward-looking statements. The content focuses on a corporate acquisition event rather than a financial report or earnings release. There are no financial statements or detailed financial performance data presented, only summary and forward-looking information. The document is not a full annual or interim report, audit report, earnings release, or investor presentation. It is a corporate announcement about a merger/acquisition transaction. Therefore, the appropriate classification is Merger & Acquisition (MA). The document length (12,349 characters) supports it being a full announcement rather than a brief notice or regulatory filing.
2024-02-08 English
Material change report - English.pdf
Regulatory Filings Classification · 100% confidence The document is a Form 51-102F3 Material Change Report filed by Aurora Cannabis Inc. It announces a material change regarding a share consolidation plan approved by the Board of Directors, including details about the consolidation ratio, expected effective date, and regulatory approvals required. The document is a regulatory filing reporting a significant corporate event but does not contain financial statements or detailed financial analysis. It is not an annual or interim report, earnings release, or any other detailed financial report. The document length is 3436 characters, which is relatively short and consistent with a regulatory announcement. Therefore, the appropriate classification is Regulatory Filings (RNS).
2024-02-02 English

Browse filings by year

7 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.